SC1-BHC-15-2018
SC1-BHC-15-2018
6 projects · €42,952,292 total EU contribution (project-level) · 53 participating organizations · 25 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€42,952,292
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (8)
- UK (6)
- BE (4)
- CH (4)
- Italy (4)
- PT (3)
- US (3)
- BF (2)
- France (2)
- Netherlands (2)
- AR (1)
- AT (1)
- BD (1)
- CM (1)
- Spain (1)
- GH (1)
- HU (1)
- IR (1)
- KE (1)
- KR (1)
- MG (1)
- MW (1)
- NZ (1)
- SE (1)
- TZ (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- UT2 projects · DE
- UGOT - GOETEBORGS UNIVERSITET/UNIVERSITY OF GOTHENBURG2 projects · SE
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE2 projects · UK
- UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO2 projects · BF
- Leiden University Medical Center1 projects · NL
- ASA SPEZIALENZYME GMBH1 projects · DE
- AURIGON LABS ZARTKORUEN MUKODO RESZVENYTARSASAG1 projects · HU
- Avivia Beheer BV1 projects · NL
- CELGENE1 projects · CH
- CEA1 projects · FR
- DNDI1 projects · CH
- Elanco Animal GmbH1 projects · DE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa Vacc-iNTS · 815439 | H2020 | €6,871,189 | €0 | Details |
Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in adults in endemic areas of sub-Saharan Africa VASA · 815643 | H2020 | €6,619,342 | €0 | Details |
Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea SHIGETECVAX · 815568 | H2020 | €8,603,990 | €0 | Details |
Vaccine for prevention and treatment of Trypanosoma cruzi infection CRUZIVAX · 815418 | H2020 | €8,391,240 | €0 | Details |
Collaboration for innovation: Establishment of a pan-nematode drug development platform HELP · 815628 | H2020 | €8,713,395 | €0 | Details |
Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis TT4CL · 815622 | H2020 | €3,753,136 | €0 | Details |